Late-Breaking Science

Scientific Sessions 2019

November 16–18

Philadelphia, Pennsylvania

Late Breaking Science I: Outside the Box: New Approaches to CVD Risk Reduction

Saturday, Nov. 16, 10:45 a.m. – 12:00 p.m.

  • DAPA-HF - Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF): Results in Nondiabetic Patients
     
  • ORION-10 - Phase 3 Trial Results: Safety and Efficacy of Inclisiran in Patients with ASCVD and Elevated LDL Cholesterol
     
  • COLCOT - The Colchicine Cardiovascular Outcomes Trial in Coronary Disease
     
  • BETonMACE - Effect of BET Protein Inhibition with Apabetalone on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Diabetes
     

Late Breaking Science II: Results for the Ischemia Trials: To Intervene or Not to Intervene

Saturday, Nov. 16, 2:00 p.m. – 3:15 p.m.

  • ISCHEMIA - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches: Primary Report of Clinical Outcomes
     
  • ISCHEMIA - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches: Primary Report of Quality of Life Outcomes
     
  • ISCHEMIA-CKD - International Study of Comparative Health Effectiveness with Medical and Invasive Approaches in Chronic Kidney Disease (ISCHEMIA-CKD): Primary Results of Clinical Outcomes

Late Breaking Science III: Controversies in Contemporary Management of AS

Saturday, Nov. 16, 5:30 p.m. – 6:45 p.m.

  • GALILEO - Primary results: Global Comparison of a Rivaroxaban-based Antithrombotic Strategy Versus an Antiplatelet-based Strategy after Transcathether Aortic Valve Replacement to Optimize Clinical Outcomes
     
  • GALILEO-4D - Randomized Clinical Trial Comparing a Rivaroxaban-based Strategy with an Antiplatelet-based Strategy for the Prevention of Subclinical Leaflet Thrombosis in Transcatheter Aortic Valves
     
  • Balloon-expandable versus Self-expandable TAVR on Paravalvular Regurgitation and 2-year Mortality: A Propensity-matched Comparison from The France-TAVI Registry
     
  • RECOVERY - Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis

Late Breaking Science IV: State of the Art Interventional Management for ACS Patients

Sunday, Nov. 17, 9:00 a.m. – 10:15 a.m.

  • TWILIGHT-ACS - Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention for Acute Coronary Syndrome
     
  • COLCHICINE-PCI - Peri-procedural Colchicine in Percutaneous Coronary Intervention
     
  • OCT COMPLETE - Non-culprit Lesion Plaque Morphology in Patients with ST-segment Elevation Myocardial Infarction: Substudy from the Complete Trial using Optical Coherence Tomography
     
  • COACT - One Year Outcomes of Coronary Angiography After Cardiac Arrest
     
  • Comparative Effectiveness and Costs of Impella versus Intra-aortic Balloon Pump in the United States

Late Breaking Science V: Challenges in Heart Failure Management

Sunday, Nov. 17, 10:45 a.m. – 12:00 p.m.

  • FUEL - Longitudinal Results from the Pediatric Heart Network: Effect of Udenafil on Exercise Performance after Fontan
     
  • DAPA-HF - Effect of Treatment Based on Age in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
     
  • DAPA-HF - Effect of treatment measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure
     
  • PARAGON-HF - Effects of Sacubitril/valsartan in Women Compared to Men with Heart Failure and Preserved Ejection Fraction
     
  • PARAGON-HF Secondary Analysis - Effect of Sacubitril/valsartan Across the Spectrum of Ejection Fraction in Heart Failure

Late Breaking Science VI: New Frontiers in Lipid Therapy

Monday, Nov. 18, 9:00 a.m. – 10:15 a.m.

  • EVAPORATE - Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients on Statin Therapy with Elevated Triglycerides (200-499mg/dl)
     
  • ORION-9 - Safety and Efficacy of Inclisiran in Patients with Heterozygous Familial Hypercholesterolemia
     
  • RNA Interference Targeting Apolipoprotein C-III in Healthy Adults, Those Having Severe Hypertriglyceridemia and in Familial Chylomicronemia Syndrome
     
  • Results Using RNA Interference to Target Hepatic Angiopoietin-like Protein 3 in Prolonging Reductions in Plasma Triglycerides and LDL-C in Humans
     
  • Treat Stroke to Target - Benefit of a Target LDL Cholesterol Less than 70 mg/dl After Ischemic Stroke due to Atherosclerosis